Lumateperone is an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar depression. As a multi-target modulator, it functions primarily as a serotonin 5-HT2A receptor antagonist… Read more





![Chemical structure of rel-Ethyl (6bR,10aR)-3-methyl-2-oxo-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2702323-64-4-rel-Ethyl-6bR10aR-3-methyl-2-oxo-236b91010a-hexahydro-1H-pyrido3445pyrrolo123-dequinoxaline-87H-carboxylate.png&w=3840&q=75)
Lumateperone is an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar depression. As a multi-target modulator, it functions primarily as a serotonin 5-HT2A receptor antagonist and a modulator of dopaminergic and glutamatergic neurotransmission. This category provides a comprehensive range of pharmaceutical reference standards for Lumateperone and its related substances, including pharmacopeial and non-pharmacopeial impurities, degradation products, metabolites, and stable isotope labelled compounds. These high-quality materials are essential for pharmaceutical laboratories performing impurity profiling, analytical method development, and rigorous quality control. By providing compounds that reflect various stress-induced degradation pathways—such as oxidation and hydrolysis—these reference materials support method validation in compliance with international regulatory guidelines. The inclusion of stable isotope labelled variants further enables precise quantitative analysis and mass spectrometry-based studies, ensuring the accuracy and reliability of analytical testing across the drug’s development and manufacturing lifecycle.